AZD0292
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
August 21, 2026
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion
August 20, 2026
BREEZE: A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
(clinicaltrials.gov)
- P2 | N=84 | Recruiting | Sponsor: AstraZeneca
New P2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases
March 19, 2026
D7700C00003: A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and chronic PsA colonization
(clinicaltrialsregister.eu)
- P1/2 | N=112 | Recruiting | Sponsor: AstraZeneca AB
New P1/2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases
March 06, 2026
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
(clinicaltrials.gov)
- P1 | N=18 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting
Enrollment closed
March 03, 2026
Azd0292, a Novel Investigational Fc-engineered Humanized Monoclonal Antibody for Bronchiectasis With Chronic Pseudomonas Aeruginosa Colonization: Results From a Randomized Phase I Study in Healthy Adults
(ATS 2026)
- No abstract available
Clinical • P1 data • Bronchiectasis • Pulmonary Disease • Respiratory Diseases
December 24, 2025
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open
November 27, 2025
CLEAR: A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
(clinicaltrials.gov)
- P2 | N=435 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open • Bronchiectasis • Pulmonary Disease • Respiratory Diseases
October 29, 2025
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: AstraZeneca
New P1 trial
July 29, 2025
CLEAR: A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
(clinicaltrials.gov)
- P2 | N=435 | Not yet recruiting | Sponsor: AstraZeneca
New P2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases
February 27, 2025
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion
October 30, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2024 ➔ Feb 2025 | Trial primary completion date: Nov 2024 ➔ Feb 2025
Trial completion date • Trial primary completion date
September 25, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | N=17 ➔ 32
Enrollment change • Enrollment closed
August 21, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=17 | Recruiting | Sponsor: AstraZeneca | N=32 ➔ 17
Enrollment change
May 29, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: AstraZeneca | N=24 ➔ 32
Enrollment change
April 18, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open
March 15, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: AstraZeneca
New P1 trial
1 to 16
Of
16
Go to page
1